Javascript must be enabled to continue!
Prevalence of HIV in the Eastern Mediterranean Region: A Systematic Review and Meta-Analysis
View through CrossRef
The Eastern Mediterranean Region (EMR) has historically been considered a low-HIV-prevalence region. However, emerging evidence suggests a rapidly evolving epidemic, with the EMR now identified as one of the few global regions where HIV incidence continues to rise. This systematic review and meta-analysis synthesizes available data on HIV prevalence across the 22 countries of the WHO Eastern Mediterranean Region, with focus on general and key populations.
A systematic search was conducted following PRISMA guidelines across PubMed, Scopus, Web of Science, Embase, and regional databases for studies published between January 1990 and December 2023. Random-effects meta-analyses were performed to pool prevalence estimates. Heterogeneity was assessed using I² statistics, and subgroup analyses were conducted by population type and subregion.
Among 38,283 screened records, 201 documents met inclusion criteria, with 115 included in meta-analyses. The estimated number of people who inject drugs (PWID) in the EMR was 864,597 (95% CI: 641,909-1,205,255), corresponding to a prevalence of 20.0 per 10,000 adults. Among PWID, the pooled prevalence of HIV was 19.22% (95% CI: 12.86-26.36%), hepatitis C virus 44.82% (29.32-61.16%), and hepatitis B virus 2.66% (0.84-7.26%). Substantial heterogeneity was observed across subregions: South Asia (primarily Pakistan) demonstrated the highest HIV prevalence among PWID at 33.20% (22.00-45.45%), while North Africa showed 8.12% (6.11-10.77%), and other subregions (East Africa, West Asia, Gulf countries) reported prevalence below 1.50%. Among female sex workers (FSW), prevalence ranged from 0-15.7% across countries, and among men who have sex with men (MSM), from 0-12.9%. The total number of people living with HIV (PLHIV) in the EMR was estimated at 530,000-610,000, with only 38% aware of their status and less than one-third receiving antiretroviral treatment.
The Eastern Mediterranean Region faces a rapidly growing HIV epidemic, characterized by concentrated epidemics among key populations, particularly PWID in Pakistan and several North African countries. Critical gaps in surveillance, low testing coverage, and underdeveloped harm reduction services threaten epidemic control. Urgent investment in targeted interventions, legal reform, and regional collaboration is required.
Keywords: HIV prevalence, Eastern Mediterranean Region, systematic review, meta-analysis, people who inject drugs, key populations, MENA
Received Date: February 25, 2025
Accepted Date: March 18, 2025
Published Date: April 01, 2025
Available Online at : https://www.ijsrisjournal.com/index.php/ojsfiles/article/view/634
International Journal of Scientific Research and Innovative Studies
Title: Prevalence of HIV in the Eastern Mediterranean Region: A Systematic Review and Meta-Analysis
Description:
The Eastern Mediterranean Region (EMR) has historically been considered a low-HIV-prevalence region.
However, emerging evidence suggests a rapidly evolving epidemic, with the EMR now identified as one of the few global regions where HIV incidence continues to rise.
This systematic review and meta-analysis synthesizes available data on HIV prevalence across the 22 countries of the WHO Eastern Mediterranean Region, with focus on general and key populations.
A systematic search was conducted following PRISMA guidelines across PubMed, Scopus, Web of Science, Embase, and regional databases for studies published between January 1990 and December 2023.
Random-effects meta-analyses were performed to pool prevalence estimates.
Heterogeneity was assessed using I² statistics, and subgroup analyses were conducted by population type and subregion.
Among 38,283 screened records, 201 documents met inclusion criteria, with 115 included in meta-analyses.
The estimated number of people who inject drugs (PWID) in the EMR was 864,597 (95% CI: 641,909-1,205,255), corresponding to a prevalence of 20.
0 per 10,000 adults.
Among PWID, the pooled prevalence of HIV was 19.
22% (95% CI: 12.
86-26.
36%), hepatitis C virus 44.
82% (29.
32-61.
16%), and hepatitis B virus 2.
66% (0.
84-7.
26%).
Substantial heterogeneity was observed across subregions: South Asia (primarily Pakistan) demonstrated the highest HIV prevalence among PWID at 33.
20% (22.
00-45.
45%), while North Africa showed 8.
12% (6.
11-10.
77%), and other subregions (East Africa, West Asia, Gulf countries) reported prevalence below 1.
50%.
Among female sex workers (FSW), prevalence ranged from 0-15.
7% across countries, and among men who have sex with men (MSM), from 0-12.
9%.
The total number of people living with HIV (PLHIV) in the EMR was estimated at 530,000-610,000, with only 38% aware of their status and less than one-third receiving antiretroviral treatment.
The Eastern Mediterranean Region faces a rapidly growing HIV epidemic, characterized by concentrated epidemics among key populations, particularly PWID in Pakistan and several North African countries.
Critical gaps in surveillance, low testing coverage, and underdeveloped harm reduction services threaten epidemic control.
Urgent investment in targeted interventions, legal reform, and regional collaboration is required.
Keywords: HIV prevalence, Eastern Mediterranean Region, systematic review, meta-analysis, people who inject drugs, key populations, MENA
Received Date: February 25, 2025
Accepted Date: March 18, 2025
Published Date: April 01, 2025
Available Online at : https://www.
ijsrisjournal.
com/index.
php/ojsfiles/article/view/634.
Related Results
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Background: HIV rapid diagnosis in The Gambia is mainly done using Determine HIV-1/2 and First Response HIV 1.2.0 or SD Bioline HIV-1/2 3.0 for screening and sero-typing of HIV res...
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Background: The HIV pandemic has attracted unprecedented scale-up in resources to curb its escalation and manage those afflicted. Although evidence from developing countries sugges...
Evaluasi peningkatan pengetahuan tentang HIV/AIDS dan sikap terhadap ODHA di SMK Gelora Jaya Nusantara
Evaluasi peningkatan pengetahuan tentang HIV/AIDS dan sikap terhadap ODHA di SMK Gelora Jaya Nusantara
Background: HIV/AIDS remains a global health problem in Indonesia, with major barriers being misunderstandings, social stigma, and ineffective educational approaches. The level of ...
Abstract 5594: Progression of paraproteinemia in HIV-positive versus HIV-negative patients
Abstract 5594: Progression of paraproteinemia in HIV-positive versus HIV-negative patients
Abstract
BACKGROUND: Paraproteinemias occur in 1 to 3% of people over the age of 50 and progress to hematological malignancies (HM) at the rate of about 1% per year....
Spatial immune dynamics in mucosal HIV infection
Spatial immune dynamics in mucosal HIV infection
<p dir="ltr">Sexual transmission is the most common mode of HIV infection, making the female genital and rectal tracts critical mucosal sites for preventing HIV transmission....

